Placebo response rate in clinical trials of fistulizing Crohn's disease: Systematic Review and Meta-analysis

Clinical Gastroenterology and Hepatology

Volumn 12, Issue 12, 2014, Pages 1981-1990

  Ford, Alexander C ^a,b   Luthra, Pavit ^a   Hanauer, Stephen B ^c   Travis, Simon P ^d   Harris, M Scott ^e   Reinisch, Walter ^f  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c NORTHWESTERN UNIVERSITY   (United States)

^d OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^e GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f MCMASTER UNIVERSITY   (Canada)

Author keywords

Fistula; IBD; Meta analysis; Placebo Effect; Randomized Controlled Trials

Indexed keywords

ADALIMUMAB; ANTIBIOTIC AGENT; AST 120; CERTOLIZUMAB PEGOL; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METRONIDAZOLE; PLACEBO; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; VEDOLIZUMAB;

ANUS; ANUS FISTULA; ARTICLE; CONTROLLED CLINICAL TRIAL (TOPIC); CROHN DISEASE; DRUG ADMINISTRATION ROUTE; HUMAN; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; COMPLICATION; FISTULA; PLACEBO EFFECT;

CROHN DISEASE; FISTULA; HUMANS; PLACEBO EFFECT; PLACEBOS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84933278329     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2014.08.038     Document Type: Article

References (32)

1. Schwartz DA, Loftus EV Jr, Tremaine WJ, et al. The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota. Gastroenterology 2002;122:875-880.
2. Beaugerie L, Seksik P, Nion-Larmurier I, et al. Predictors of Crohn's disease. Gastroenterology 2006;130:656.
3. van Assche G, Dignass A, Reinisch W, et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: special situations. J Crohns Colitis 2010;4:63-101.
4. de Craen AJ, Moerman DE, Heisterkamp SH, et al. Placebo effect in the treatment of duodenal ulcer. Br J Clin Pharmacol 1999;48:853-860.
5. Ilnyckyj A, Shanahan F, Anton PA, et al. Quantification of the placebo response in ulcerative colitis. Gastroenterology 1997; 112:1854-1858.
6. Su C, Lichtenstein GR, Krok K, et al. A meta-analysis of the placebo rates of remission and response in clinical trials of active Crohn's disease. Gastroenterology 2004;126:1257-1269.
7. Tine F, Rossi F, Sferrazza A, et al. Meta-analysis: remission and response from control arms of randomized trials of biological therapies for active luminal Crohn's disease. Aliment Pharmacol Ther 2008;27:1210-1223.
8. Pascua M, Su C, Lewis JD, et al. Meta-analysis: factors predicting post-operative recurrence with placebo therapy in patients with Crohn's disease. Aliment Pharmacol Ther 2008;28:545-556.
9. Renna S, Camma C, Modesto I, et al. Meta-analysis of the placebo rates of clinical relapse and severe endoscopic recurrence in postoperative Crohn's disease. Gastroenterology 2008; 135:1500-1509.
10. Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn's disease activity index: National Cooperative Crohn's Disease Study. Gastroenterology 1976;70:439-444.
11. Sandborn WJ, Feagan BG, Hanauer SB, et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology 2002; 122:512-530.
12. Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions: version 5.0.2. Available at: www.cochrane-handbook.org 2009. Accessed July 9, 2014.
13. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-188.
14. Higgins JPT, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. Br Med J 2003;327:557-560.
15. Lau J, Ioannidis JP, Schmid CH. Summing up evidence: one answer is not always enough. Lancet 1998;351:123-127.
16. Colombel JF, Schwartz DA, Sandborn WJ, et al. Adalimumab for the treatment of fistulas in patients with Crohn's disease. Gut 2009;58:940-948.
17. Fukuda Y, Takazoe M, Sugita A, et al. Oral spherical adsorptive carbon for the treatment of intractable anal fistulas in Crohn's disease: a multicenter, randomized, double-blind, placebo-controlled trial. Am J Gastroenterol 2008;103: 1721-1729.
18. Maeda Y, Ng SC, Durdey P, et al. Randomized clinical trial of metronidazole ointment versus placebo in perianal Crohn's disease. Br J Surg 2010;97:1340-1347.
19. Present DH, Korelitz BI, Wisch N, et al. Treatment of Crohn's disease with 6-mercaptopurine: a long-term, randomized, double-blind study. N Engl J Med 1980;302:981-987.
20. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999;340:1398-1405.
21. Sandborn WJ, Feagan BG, Radford-Smith G, et al. CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial. Gut 2004; 53:1485-1493.
22. Sandborn WJ, Present DH, Isaacs KL, et al. Tacrolimus for the treatment of fistulas in patients with Crohn's disease: a randomized, placebo-controlled trial. Gastroenterology 2003; 125:380-388.
23. Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007; 357:228-238.
24. Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007;146:829-838.
25. Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med 2013;369:711-721.
26. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004;350:876-885.
27. Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 2007;357:239-250.
28. Reinisch W, Travis S, Hanauer S, et al. AST-120 (spherical carbon adsorbent) in the treatment of perianal fistulae in mildto-moderate Crohn's isease: FHAST-1, a phase 3, multicenter, placebo-controlled study. Inflamm Bowel Dis 2014; 20:872-881.
29. Karmiris K, Bielen D, Vanbeckevoort D, et al. Long-term monitoring of infliximab therapy for perianal fistulizing Crohn's disease by using magnetic resonance imaging. Clin Gastroenterol Hepatol 2011;9:130-136.
30. Bouguen G, Siproudhis L, Gizard E, et al. Long-term outcome of perianal fistulizing Crohn's disease treated with infliximab. Clin Gastroenterol Hepatol 2013;11:975-981.
31. Kaptchuk TJ, Friedlander E, Kelley JM, et al. Placebos without deception: a randomized controlled trial in irritable bowel syndrome. PLoS One 2010;5:e15591.
32. Mommaerts JL, Devroey D. The placebo effect: how the subconscious fits in. Perspect Biol Med 2012;55:43-58.